(Sharecast News) - Novo Nordisk's attempt to repurpose its blockbuster diabetes and weight-loss drug semaglutide for Alzheimer's disease suffered a decisive setback on Monday, after two major phase three trials failed to show that the medicine could slow cognitive decline in early-stage patients.
Shares in the Danish drugmaker fell in early...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE